Biotech | February 22, 2022
Prestige BioPharma’s facility receives EU-GMP certification
The facility will manufacture its Herceptin biosimilar, Tuznue
The facility will manufacture its Herceptin biosimilar, Tuznue
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
Subscribe To Our Newsletter & Stay Updated
